+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antithrombotic Drugs Market by Drug Class, Route of Administration, Application, End User, Age Group - Global Forecast 2025-2030- Product Image
Antithrombotic Drugs Market by Drug Class, Route of Administration, Application, End User, Age Group - Global Forecast 2025-2030- Product Image
Sale

Antithrombotic Drugs Market by Drug Class, Route of Administration, Application, End User, Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013888
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antithrombotic Drugs Market grew from USD 40.08 billion in 2023 to USD 42.47 billion in 2024. It is expected to continue growing at a CAGR of 6.04%, reaching USD 60.45 billion by 2030.

The scope and definition of antithrombotic drugs encompass agents used to inhibit blood clot formation, thereby mitigating risk in conditions such as coronary artery disease, cerebrovascular accidents, and deep vein thrombosis. The necessity of these drugs stems from their critical role in preventing heart attacks, strokes, and related life-threatening events. They are implemented in clinical settings to manage and treat conditions requiring anticoagulation or antiplatelet therapy. End users primarily include hospitals, clinics, and outpatient settings where patients at risk of thrombotic events are managed. The market is currently driven by the increasing prevalence of cardiovascular diseases, rising awareness towards prophylactic treatments, and advancements in pharmacology that enhance drug efficacy while minimizing side effects. Market insights underscore the impact of an aging population and an uptick in lifestyle diseases globally as key growth influencers. However, limitations such as the high cost of novel drugs, stringent regulatory environments, and potential side effects pose challenges. Moreover, patent expirations of significant drugs may restrain market dynamics. Latest opportunities lie in personalized medicine, particularly developments in pharmacogenomics that tailor therapies to individual genetic profiles, offering a new frontier in precise treatment regimes. Companies that invest in R&D activities to develop innovative delivery mechanisms, like nanotechnology-enabled systems, and explore untapped markets in underdeveloped regions could capture significant market share. Moreover, collaborations between pharmaceutical companies and research institutions could accelerate breakthroughs and commercialized applications of newer agents. Innovations in anticoagulant safety profiles and dosing regimens mark pivotal directions for research, aiming to enhance patient compliance and diminish adverse effects. This market is dynamic and competitive, characterized by continual innovations and healthcare reforms, requiring businesses to remain agile and informed on regulatory and technological advancements to sustain and amplify growth.

Understanding Market Dynamics in the Antithrombotic Drugs Market

The Antithrombotic Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing geriatric population susceptible to thrombotic events requiring consistent medication
    • Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
    • Rising healthcare expenditure and investment in medical research boosting drug development
    • Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
  • Market Restraints
    • Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
    • Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
  • Market Opportunities
    • Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
    • Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
    • Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
  • Market Challenges
    • Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
    • Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market

Exploring Porter’s Five Forces for the Antithrombotic Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Antithrombotic Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antithrombotic Drugs Market

External macro-environmental factors deeply influence the performance of the Antithrombotic Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antithrombotic Drugs Market

The Antithrombotic Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antithrombotic Drugs Market

The Antithrombotic Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antithrombotic Drugs Market

The Antithrombotic Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombotic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alere Inc., Aralez Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Portola Pharmaceuticals, Roche Holding AG, Sanofi S.A., and The Medicines Company.

Market Segmentation & Coverage

This research report categorizes the Antithrombotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Antiplatelet Agents
      • Aspirin
      • Clopidogrel
      • Prasugrel
    • Direct Thrombin Inhibitors
      • Dabigatran
    • Factor Xa Inhibitors
      • Apixaban
      • Edoxaban
      • Rivaroxaban
    • Vitamin K Antagonists
      • Warfarin
  • Route of Administration
    • Injectable
    • Oral
  • Application
    • Acute Coronary Syndrome
    • Atrial Fibrillation
    • DVT and PE
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing geriatric population susceptible to thrombotic events requiring consistent medication
5.1.1.2. Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
5.1.1.3. Rising healthcare expenditure and investment in medical research boosting drug development
5.1.1.4. Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
5.1.2. Restraints
5.1.2.1. Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
5.1.2.2. Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
5.1.3. Opportunities
5.1.3.1. Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
5.1.3.2. Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
5.1.3.3. Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
5.1.4. Challenges
5.1.4.1. Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
5.1.4.2. Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Antithrombotic Drugs Market, by Drug Class
6.1. Introduction
6.2. Antiplatelet Agents
6.2.1. Aspirin
6.2.2. Clopidogrel
6.2.3. Prasugrel
6.3. Direct Thrombin Inhibitors
6.3.1. Dabigatran
6.4. Factor Xa Inhibitors
6.4.1. Apixaban
6.4.2. Edoxaban
6.4.3. Rivaroxaban
6.5. Vitamin K Antagonists
6.5.1. Warfarin
7. Antithrombotic Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral
8. Antithrombotic Drugs Market, by Application
8.1. Introduction
8.2. Acute Coronary Syndrome
8.3. Atrial Fibrillation
8.4. DVT and PE
9. Antithrombotic Drugs Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.4. Hospitals
10. Antithrombotic Drugs Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Americas Antithrombotic Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antithrombotic Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antithrombotic Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTITHROMBOTIC DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTITHROMBOTIC DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PRASUGREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DVT AND PE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 116. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 119. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 125. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 128. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 143. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 145. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 197. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 234. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 261. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 279. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 282. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 308. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 317. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 318. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 322. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
TABLE 324. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 325. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 326. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 327. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 331. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 332. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTI

Companies Mentioned

The leading players in the Antithrombotic Drugs market, which are profiled in this report, include:
  • Abbott Laboratories
  • Alere Inc.
  • Aralez Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Portola Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • The Medicines Company

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 42.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 60.45 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Factor XI inhibitors - Pipeline Insight, 2024 - Product Image

Factor XI inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Antiplatelet Market by Drug Type, Mode of Administration, Application, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Antiplatelet Market by Drug Type, Mode of Administration, Application, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease - Product Image

Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease

  • Book
Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030 - Product Image

Behcet Disease Drug Market by Drug Type, Route of Administration, End User, Drug Class, Stage of Disease, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Factor Xa inhibitors - Pipeline Insight, 2024 - Product Image

Factor Xa inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Antithrombotics Market

Antithrombotics are drugs used to prevent the formation of blood clots, which can lead to cardiovascular diseases such as stroke and heart attack. These drugs work by inhibiting the activity of clotting factors in the blood, thus preventing the formation of clots. Common antithrombotics include aspirin, clopidogrel, warfarin, and heparin. Aspirin is the most widely used antithrombotic, and is often prescribed to reduce the risk of stroke and heart attack. Clopidogrel is used to prevent blood clots in patients with coronary artery disease, while warfarin is used to prevent and treat blood clots in patients with atrial fibrillation. Heparin is used to prevent and treat deep vein thrombosis and pulmonary embolism. The antithrombotics market is highly competitive, with many large pharmaceutical companies offering a range of products. Some of the major players in the market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. These companies are continuously developing new products to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.